Please login to the form below

Not currently logged in
Email:
Password:

Genzyme and Icahn reach proxy settlement

Genzyme has announced that it has reached an agreement with investor Carl Icahn to settle a proxy content

Genzyme has announced that it has reached an agreement with investor Carl Icahn to settle a proxy content.

As part of the agreement, Icahn will withdraw his slate of four nominees for Genzyme's board of directors and he will support the company's nominees. As a result, two of Icahn's supporters, Dr Steven Burakoff and Dr Eric Ende, will join Genzyme's board of directors immediately following the annual meeting of shareholders on June 16.

"Over the past year, we have made substantial progress in enacting operational and organisational changes to return to our historical path of sustainable growth," said Henri A Termeer, Genzyme's chairman and chief executive officer.

"This agreement provides a pragmatic and constructive solution that allows us to focus on continuing to strengthen and build the company to create value for our shareholders," he continued.

Dr Burakoff, is professor of medicine, haematology and medical oncology at the Mount Sinai School of Medicine and director of the Tisch Cancer Institute at the Mount Sinai Medical Center.

Dr Ende is a former biotechnology analyst with Merrill Lynch & Co. Inc.

Talking about the resolution, Icahn said: "I am always pleased when a proxy fight can be avoided. I believe Drs Burakoff and Ende will add significant medical and financial expertise to the Genzyme board."

Following these two appointments and an additional appointment of Dr Dennis M Fenton, former executive vice president of operations at Amgen, Genzyme's board will consist of 13 members.

10th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics